Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label randomized study of amcenestrant versus physician's choice endocrine monotherapy in ER-positive, HER2-negative advanced breast cancer
MOH_2020-01-21_008655Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of amcenestrant in breast cancer (2 arms), sponsored by Sanofi. Started Jan 2020; status: completed.
02
Drugs
amcenestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on MOH_2020-01-21_008655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-01-21_008655.